Diffusion-Weighted MRI of Malignant versus Benign Portal Vein Thrombosis by 김기황 et al.
533Copyright © 2016 The Korean Society of Radiology
Diffusion-Weighted MRI of Malignant versus Benign 
Portal Vein Thrombosis
Jhii-Hyun Ahn, MD, Jeong-Sik Yu, MD, Eun-Suk Cho, MD, Jae-Joon Chung, MD,  
Joo Hee Kim, MD, Ki Whang Kim, MD
All authors: Department of Radiology, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul 06273, Korea
Objective: To validate the diffusion-weighted MRI (DWI) for differentiation of benign from malignant portal vein 
thrombosis.
Materials and Methods: The Institutional Review Board approved this retrospective study and waived informed consent. A 
total of 59 consecutive patients (52 men and 7 women, aged 40–85 years) with grossly defined portal vein thrombus (PVT) 
on hepatic MRI were retrospectively analyzed. Among them, liver cirrhosis was found in 45 patients, and hepatocellular 
carcinoma in 47 patients. DWI was performed using b values of 50 and 800 sec/mm2 at 1.5-T unit. A thrombus was 
considered malignant if it enhanced on dynamic CT or MRI; otherwise, it was considered bland. There were 18 bland thrombi 
and 49 malignant thrombi in 59 patients, including 8 patients with simultaneous benign and malignant PVT. Mean apparent 
diffusion coefficients (ADCs) of benign and malignant PVTs were compared by using Mann-Whitney U test. Diagnostic 
accuracy was evaluated using receiver operating characteristic (ROC) curve analysis.
Results: The mean ADC ± standard deviation of bland and malignant PVT were 1.00 ± 0.39 x 10-3 mm2/sec and 0.92 ± 0.25 
x 10-3 mm2/sec, respectively; without significant difference (p = 0.799). The area under ROC curve for ADC was 0.520. An 
ADC value of > 1.35 x 10-3 mm2/sec predicted bland PVT with a specificity of 94.6% (95% confidence interval [CI]: 84.9–
98.9%) and a sensitivity of 22.2% (95% CI: 6.4–47.6%), respectively.
Conclusion: Due to the wide range and considerable overlap of the ADCs, DWI cannot differentiate the benign from 
malignant thrombi efficiently.
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INTRODUCTION
A variety of conditions including cirrhosis, neoplastic 
diseases, infection, intra-abdominal inflammatory diseases, 
myeloproliferative disorders, and hypercoagulable states 
could result in portal vein thrombosis (PVT) (1). In some 
autopsy reviews, the overall incidence of PVT ranges from 
0.05% to 1% (1, 2). Cirrhosis is the most common cause 
of benign PVT in adults and is present in 24% to 32% 
of the patients with PVT, while the incidence of PVT is 
also increased in the patients with primary or secondary 
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without PVT on MRI. Therefore, 59 patients, 52 men (average 
age, 60.3 years; range, 43–85 years) and 7 women (average 
age, 59.9 years; range, 40–72 years) with an overall average 
age of 60.2 years (range, 40–85 years) were finally enrolled 
in our study. Forty-five of 59 patients had liver cirrhosis, 
and 47 of those had HCCs. At the time of MRI, the Child-
Pugh classification of each group of patients was as follows: 
class A, n = 34; class B, n = 10; class C, n = 1. HCCs were 
established in 47 patients, based on pathologic results 
of operation in 3 patients and non-invasive diagnostic 
criteria of European Association for the Study of the Liver 
guidelines for the other patients (23).
Reference Standard for Characterization of Portal Vein 
Thrombosis
Two abdominal radiologists with 8- and 5-years of 
experience in abdominal MRI described the location of 
thrombi and categorized the thrombi as bland or malignant 
on the basis of known published criteria independently and 
were in agreement with each other. The main feature used 
to differentiate tumor thrombus from bland thrombus was 
the presence or absence of enhancement. Enhancement of 
PVT was considered present at contrast-enhanced MRI when 
obvious enhancement was observed on subtraction images. 
Vessel expansion by thrombus was one of the diagnostic 
criteria suggestive of malignant thrombus, but it can be 
seen in both bland and malignant thrombi (11, 24). Hence, 
we did not use vessel expansion as the criteria. In the 
cases of benign PVT without HCC, thrombi were resolved, 
decreased in size, or had no change without any treatment 
on follow-up imaging. The cases of mixed malignant and 
bland thrombus within the same vessel were recorded as 
malignant thrombus. On the other hand, cases of bland 
thrombus located at the separate vessels were recorded as 
individual benign thrombi.
MR Imaging Technique
MRI was performed using a 1.5-T system (Magnetom 
Avanto; Siemens, Erlangen, Germany) equipped with high 
performance gradients (maximum amplitude 45 mT/m) and 
a six-element phased-array surface coil. After obtaining 
localizer images in the supine position, spectrally fat-
suppressed breath-hold T2-weighted turbo spin echo images 
(repetition time [TR] = 3020 ms, echo time [TE] = 109 ms, 
flip angle = 150°, echo train length = 13, slice thickness = 
6 mm) or half-Fourier single-shot turbo spin-echo images 
(TR = infinite, TE = 85 ms, slice thickness = 6–8 mm) were 
malignancies (2-5). Patients with cirrhosis or neoplastic 
diseases may develop either benign or malignant PVT; 
moreover, benign and malignant thrombi can be coexistent 
(3, 6). For the patients in the neoplastic condition, the 
presence of malignant PVT is an important factor during 
the tumor staging, in addition to determining the proper 
therapeutic approach and their prognosis (6-9).
Until recently, imaging differentiation of the benign from 
malignant PVT has depended on the finding of contrast 
enhancement and luminal expansion on CT or MRI (5, 10-
14). In a recent study, Catalano et al. (15) suggested that 
diffusion-weighted MRI (DWI) enabled discrimination of 
bland and neoplastic portal vein thrombi by a clear-cut 
difference of apparent diffusion coefficient (ADC). With 
the technical development of high-performance magnet 
and parallel imaging with multi-channel surface coil, 
DWI has been generalized for the body imaging in the 
past few years. By the difference of Brownian motion of 
water molecules in different tissues, many investigators 
reported the usefulness of DWI to differentiate benign 
from malignant hepatic lesions (16-22). Depending on our 
experience of daily practice, however, it was not always 
easy to distinguish tumorous from bland thrombus, which 
also can restrict the molecular motion on DWI. In the 
present study, we tried to validate the DWI again in the 
differentiation between benign and malignant PVT.
MATERIALS AND METHODS
Patients
Our Institutional Review Board approved this 
retrospective study and did not require informed consent for 
patient data review. The selection process included a review 
of the radiology database, including the official reports 
(for the words “portal vein thrombosis”, “thrombosis”, and 
“thrombus”) of image interpretation in our picture archiving 
and communication systems (PACS) for gadoxetic acid-
enhanced liver MRI, including DWIs, by a study coordinator 
and a radiologist with a 16-years of experience in abdominal 
imaging. Total 67 patients had PVT, regardless of the nature 
of the thrombus, during a 5 year period from October 2008 
to October 2013. From this initial group of 67 patients, 
first we excluded 6 patients with a malignancy other than 
hepatocellular carcinoma (HCC; gallbladder cancer, n = 2; 
gastric cancer, n = 2; intrahepatic cholangiocarcinoma, n = 
1; unknown primary cancer, n = 1). Thereafter, we excluded 
2 patients with thrombosis in the superior mesenteric vein 
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obtained on the axial plane. After obtaining a double-echo 
chemical shift gradient-echo sequence (TR = 100 ms, first-
echo TE = 2.0 ms [opposed-phase], second-echo TE = 4.2 ms 
[in-phase], flip angle = 70°), contrast-enhanced imaging 
was obtained using a three-dimensional gradient echo 
sequence (VIBE; Siemens, Erlangen, Germany) with ultrafast 
image reconstruction by parallel imaging algorithms 
(GRAPPA factor = 2) on the axial plane (TR = 4.4 ms, TE = 
2.1 ms, flip angle = 10°, matrix = 448 x 224, field of view = 
271 x 379 mm, slice thickness = 5 mm, slice spacing = 2.5 
mm, slices = 72) during a 20-second breath-holding period. 
A dynamic series consisted of one pre-contrast series 
followed by three successive post-contrast series, including 
early arterial, late arterial and portal phase imaging with 
34-second intervals (20 seconds for image acquisition with 
breath-holding and 14 seconds for re-breathing) for the 
start of each phase imaging. To determine the time delay 
for early arterial phase imaging, a timing examination 
was performed according to the previously described 
method (25). The postcontrast series was performed after 
administering a bolus injection of gadoxetic acid disodium 
(0.1 mL/kg) (Primovist; Bayer Healthcare, Berlin, Germany) 
at a rate of 2 mL/s followed by a saline flush using a 
power injector. Five and 20 minutes after contrast material 
injection, delayed phase and hepatobiliary phase images 
were added using the same VIBE technique, respectively.
Approximately 7 minutes after injection of the contrast 
agent, respiratory-triggered DWI sequences were performed 
with the single-shot spin-echo echo planar imaging 
sequence with motion probing gradients in three directions. 
For monitoring respiration, the prospective acquisition 
correction technique, in which the diaphragmatic 
position is assessed periodically by navigator echoes, was 
implemented. These sequences used two b factors: 50 and 
800 s/mm2. The other technical parameters were as follows: 
TR = 3900 ms, TE = 75 ms, matrix = 156 x 192, average = 6, 
slices = 52 (26 slices for each b factor), thickness = 6 mm 
with interslice gap 30%, and bandwidth = 1735 Hz/pixel. 
ADC maps corresponding to each slice were automatically 
acquired using all b factors. All scans were sent to the PACS.
Image Analysis
Quantitative analysis was performed by two other 
abdominal radiologists with 3- and 17-years of experience 
in abdominal MRI, who were unaware of the bland or 
Fig. 1. Patient flow chart. BT = benign thrombosis, HCC = hepatocellular carcinoma, LC = liver cirrhosis, PVT = portal vein thrombosis, TT = 
tumor thrombosis
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Fig. 2. Box plot showing ADC (x 10-3 mm2/sec) of bland and 
malignant portal vein thrombi (PVT). There is no significant 
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neoplastic nature of the thrombus and had no access to the 
other sequences and images. They had provided information 
about the location of thrombosis from other two reviewers 
who had categorized the thrombi as bland or malignant. 
Each reader drew oval regions of interest in thrombi as large 
as possible, which included at least two-thirds of the area 
of the PVT, at a workstation (Centricity 2.0, GE Healthcare, 
Chicago, IL, USA) to measure the ADC of each thrombus 
on ADC map. ADC values obtained from the two readers 






Fig. 3. Bland thrombosis of portal vein in 65-year-old man without underlying disease.
Filling defect is noted in right portal vein (arrows) on portal phase (B) contrast-enhanced MRI, which shows no enhancement on subtraction 
image (A). Portal vein thrombosis exhibits central high SI (arrows) with peripheral low SI (arrowheads) at DWI (b = 800 sec/mm2) (C) and 
central low ADC value (0.86 x 10-3 mm2/sec) (arrows) with peripheral high ADC value (arrowheads) on corresponding ADC map (D). Peripheral 
bright region on ADC map representing vessel wall or increased capillary flow by formation of collateral vessels. ADC = apparent diffusion 
coefficient, DWI = diffusion-weighted MRI, SI = signal intensity
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Statistical Analysis
Mean ADCs of benign and malignant PVTs were compared 
by using Mann-Whitney U test. A p value < 0.05 was 
considered to indicate a statistically significant difference. 
Diagnostic accuracy was evaluated using receiver operating 
characteristic (ROC) curve analysis with a calculation of 
the area under the ROC curve. Statistical analyses were 
performed with SPSS version 16.0 for Windows (SPSS Inc., 
Chicago, IL, USA).
RESULTS
There were 18 bland thrombi and 49 malignant thrombi in 
59 patients, including 8 patients with simultaneous benign 
and malignant PVT. All malignant thrombi were combined 
with hepatocellular carcinoma (Fig. 1).
The mean ADC ± standard deviation of bland and 
malignant PVT were 1.00 ± 0.39 x 10-3 mm2/sec (range, 
0.45–2.01 x 10-3 mm2/sec) and 0.92 ± 0.25 x 10-3 mm2/
sec (range, 0.52–1.69 x 10-3 mm2/sec), respectively (Fig. 









Fig. 4. Bland and malignant thrombus in 58-year-old man with liver cirrhosis and infiltrative HCC.
Arterial phase contrast-enhanced MRI (A) and subtraction image (B) show infiltrative HCC (*) in left hepatic lobe and enhancing thrombus in 
right portal vein (arrows). HCC and portal vein tumor thrombus display similar high SI on DWI (b = 800 sec/mm2) (C) and low ADC value on 
corresponding ADC map (D). Non-enhancing bland thrombus (arrowheads) is also seen in main portal vein (E, F). Bland thrombus shows low 
SI on DWI (b = 800 sec/mm2) (G) and low ADC value on corresponding ADC map (H). Tumor thrombus (1.06 x 10-3 mm2/sec) shows higher ADC 
value than benign thrombus (0.73 x 10-3 mm2/sec) on ADC map. ADC = apparent diffusion coefficient, DWI = diffusion-weighted MRI, HCC = 
hepatocellular carcinoma, SI = signal intensity
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and malignant thrombus (p = 0.799). Some chronic bland 
thrombi show dark central region surrounded by a brighter 
region on ADC map (Fig. 3). In 6 of 8 patients who had 
both benign and malignant PVT, tumor thrombus showed 
rather higher ADC value than benign thrombus (Fig. 4).
The mean area under ROC curve for ADC was 0.520 (Fig. 5). 
Based on the ROC curve, we determined that the best cut-
off value for differentiating bland and malignant PVT was 
1.35 x 10-3 mm2/sec. With ADCs greater than 1.35 x 10-3 
mm2/sec, the sensitivity and specificity of the diagnosis 
of bland PVT were 22.2% (95% confidence interval [CI]: 
6.4–47.6%) and 94.6% (95% CI: 84.9–98.9%), respectively.
DISCUSSION
Tumor thrombus in the portal vein is an important 
complication and a prognostic factor in the patients with 
hepatocellular carcinoma (7, 26, 27). The reference standard 
for evaluating PVT is histopathologic examination. However, 
in clinical practice, imaging diagnosis has replaced open 
laparotomy or percutaneous biopsy for characterizing PVT. 
The Doppler ultrasonography (US), contrast-enhanced US, 
contrast-enhanced CT, and contrast-enhanced MRI have 
been proven to be suitable modalities for differentiation,  
and several imaging characteristics of malignant PVT have 
been reported. Intrathrombus neovascularity, venous 
expansion, and direct invasion of the portal vein are 
independently diagnostic of malignant PVT on CT and MRI 
(5, 10-14). Moreover, PVT continuous with parenchymal 
hepatocellular carcinoma and generalized enhancement of 
a PVT, strongly suggests malignant PVT on these sectional 
imaging studies. However, application of these criteria is 
limited in some patients with poor renal function or history 
of previous reaction to contrast material.
There have been many investigations for the benefits 
of DWI in differentiating benign from malignant hepatic 
lesions. ADCs for malignant hepatic lesions were 
significantly lower than that for benign hepatic lesions 
with good sensitivity, specificity, and accuracy, though 
cut-off values for ADC varied considerably (28, 29). In a 
recent study by Catalano et al. (15), the mean ADC of 6 
bland thrombi was significantly higher (approximated to 
free fluid) than that of malignant thrombi, and the authors 
concluded that DWI could provide supportive information 
for discriminating between them in the same context. In 
our study, however, the mean ADCs of bland and malignant 
thrombi were rather similar to each other (the area of under 
the ROC curve was 0.520), and could not be differentiated 
from each other using the best cut-off value. In this 
situation, DWI could not add any information to the pre-
established criteria, which were commonly used as reference 
standards for the diagnosis of benign and malignant PVT, in 
the previous studies including ours and that of Catalano et 
al. (15).
The signal intensities of blood clot were affected by T2 
shine-through or T2 black-out effects resulting in various 
signal intensities on DWI, depending on the age of the 
hemorrhage in the several investigations dealing with 
intracranial hemorrhage (30-32). For ADCs, however, most 
hematomas tended to show low ADCs in their studies (30-
32). Decreased ADC in hyperacute hematoma is referable to 
high viscosity related to shrinkage of extracellular space. 
On the acute and early subacute stages of hematoma, 
a magnetic susceptibility effects, which is caused by 
paramagnetic intracellular deoxyhemoglobin in acute 
hematoma and paramagnetic intracellular methemoglobin 
in early subacute hematoma, led to a drop in ADC (33-35). 
At the late subacute stage of hematoma, high viscosity 
caused by extracellular distribution of intracellular contents 
and high cellularity resulting from the infiltration of 
inflammatory cells and macrophages, lead to low ADC (30, 
36). For these reasons, bland PVT might have low ADC like 
Fig. 5. Receiver operating characteristic curve analyses 
showing diagnostic accuracy of ADC value for differentiating 
between bland and malignant PVT. Area under curve was 0.520. 
When threshold ADC value of greater than 1.35 x 10-3 mm2/
sec, sensitivity and specificity of diagnosis of bland PVT were 
22.2% (95% confidence interval [CI]: 6.4–47.6%) and 94.6% 
(95% CI: 84.9–98.9%), respectively. ADC = apparent diffusion 
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malignant PVT, as in the present study. As a reply to an 
argument by Yu et al. (37) for this issue, Catalano et al. 
(15) suggested difference in the clotting process between 
the intracranial closed space and intravascular space with 
flowing blood. Despite their suggestion, it is still difficult 
to explain the discrepancy between our results and those 
reported by Catalano et al. (15). Only one exceptional 
situation that could show such high ADC is mostly in 
liquefied hematoma in a closed space allowing free 
molecular motion in the lesion (30). Such condition seems 
unlikely in the vascular lumen with flowing blood, but we 
guess it may be possible in some limited cases consisting 
of the inner liquefied component surrounded by fibrotic 
wall in the old intravascular hematoma. Some chronic bland 
thrombi show low ADC value at central portion with high 
ADC value at peripheral region on ADC map. The DWI of 
these thrombi was the inverse of the ADC map. Peripheral 
high ADC might represent the area of increased blood flow 
by the formation of perivascular collateral vessels around 
the thrombi. In these cases, surrounding high ADC value 
can influence on ADC value of bland thrombi depending on 
the ROI localization.
Our study had several limitations. First of all, pathologic 
correlation was not confirmed in every patient due to the 
retrospective nature of this study. We mainly established 
the nature of the PVT based on the findings of enhanced CT 
or MRI. But, the characterizing of PVT was clear on follow-
up imaging studies, particularly in the cases of bland PVT. 
Our primary scope of this study was to verify or to make 
an argument on the conclusion of previous DWI study for 
PVT with the use of similar study design. Although the 
number of patients was larger than the previous study, the 
sample size was still limited for confirmed conclusions. 
For this reason, individual analysis on age-related changes 
of ADC value in thrombus was impossible. Further study is 
expected with larger population dealing with the ADCs of 
PVT combined with histological proof. Lastly, regarding a 
topic of imaging differentiation of the thrombus nature by 
DWI, the negative results of this study would have limited 
impacts except the rebuttal of a previous study (15).
In conclusion, due to the wide range and considerable 
overlap of the ADCs, DWI hardly differentiated the benign 
from malignant PVT in this study. Bland PVT is a benign 
condition; however, according to its nature of diffusion 
restriction during the clotting process, the low ADC value, 
the common feature of benign and malignant PVT on DWI, 
has very limited value in the characterization of PVT during 
the clinical practice.
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